ML
Marcus Linsley
Chief Financial Officer · Meridian Oncology
London, England, United Kingdom · LinkedIn ↗
Background
CFO with fifteen years building finance functions inside UK oncology and rare-disease biotechs, currently at Meridian Oncology following CFO seats at Kestrel Biopharma and Glasslake Therapeutics. I've led venture rounds from pre-seed through Series C, run two target-side M&A processes to close, and spent four years as…
Experience6 yrsCompanies7
Career History
Oct 2025 – Present9 moChief Financial Officer at Kestrel Biopharma
Series A → Series B14 → 41 FTEs£34M Series BOncology · ADC platform
Led the £34M Series B from the inside with Molten and CIC; ADC platform, headcount 14→41 across the raise.
Jan 2024 – Present2 yr 6 moChief Financial Officer at Glasslake TherapeuticsLondon, England, United Kingdom
Seed → Series A7 → 22 FTEs£18M Series AOncology · Small molecule
Ran the £18M Series A end-to-end with Cambridge Innovation Capital; joined at 7 FTEs, closed the round at 22.
Jan 2024 – Sept 20248 moInterim CFO at Ridgeline Bio
Oct 2023 – Dec 20232 moConsultant CFO at Ridgeline Bio
Education
Bachelor's degree — Ravenscourt Institute (1989–1993)
Qualified by examination, Management Accounting, FCMA, CGMA — Ashbury College (1994–1996)